Sign Out
Do not give this product intravascularly (risk of shock). Injections have to be made intramuscularly, and care should be taken to draw back the plunger of the syringe before injection in order to be certain that the needle is not in a blood vessel.
True allergic responses to human antitetanus immunoglobulin given in the prescribed intramuscular manner are rare. In the case of shock, treatment should follow the guidelines of shock therapy.
Intolerance to immunoglobulins is likely to develop in the very rare cases of IgA deficiency, when the patient has antibodies against IgA.
Patients should be observed for at least 20 minutes after administration.
When medicinal products prepared from human blood or plasma are administered, infectious diseases due to transmission of infective agents cannot be totally excluded. This also applies to pathogens of unknown nature. The risk of transmission of infective agents is however reduced by: selection of donors by a medical interview and screening of individual donations and plasma pools for HBsAg and antibodies to HIV and HCV; testing of plasma pools for HCV genomic material; inactivation/removal procedures included in the production process that have been validated using model viruses. These procedures are considered effective for HIV, HCV, HAV and HBV.
The viral inactivation/removal procedures may be of limited value against non-enveloped viruses such as parvovirus B19 and other transmissible infectious agents.
